BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Core Insights - BriaCell Therapeutics Corp. is set to present positive Phase 2 survival and Phase 3 biomarker data at the 2025 San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025, highlighting the potential of their novel immunotherapies in cancer treatment [1][7] Group 1: Presentation Details - The company will present three posters, including a pivotal Phase 3 trial analysis involving 116 patients, which shows an excellent safety profile and improved progression-free survival (PFS) in specific breast cancer subtypes [3][7] - A Phase II study on the Bria-IMT regimen combined with an anti-PD-1 checkpoint inhibitor demonstrated continued overall survival benefits in 54 metastatic breast cancer patients [4] - Analysis of blood cytokines from 30 patients suggests that Th1 biased cytokines may serve as predictive biomarkers for clinical responses to the Bria-IMT regimen [5] Group 2: Company Statements - The President & CEO of BriaCell expressed optimism about the survival and biomarker data, emphasizing the commitment to improving outcomes for cancer patients with unmet medical needs [2] - The Chief Medical Officer highlighted the significance of biomarker and patient subgroup data in identifying patients likely to benefit from their treatment [2]